Hasan Ali ALTUNBAŞ, Mustafa KAPLAN, Ömer Öztürk, İlyas Tenlik

Subklinik Hipotiroidide Kolesterol Düzeyleri ve Levotiroksin Tedavisinin Kolesterol Düzeyleri Etkisi

GİRİŞ ve AMAÇ: Bu çalışmada subklinik hipotiroidi (SH) tanısı alan hastalarda açlık ve postprandial kolestrol düzeyleri araştırılmış ve tiroksin tedavisinin bu kolestrol düzeylerine etkisinin olup olmadığı incelenmiştir. YÖNTEM ve GEREÇLER: Çalışmaya yeni tanı almış 50 SH’li ve 25 ötiroid hasta alındı. Başvuran ilk 25 SH’li hasta tedavi grubunu (grup I) ve ikinci 25 SH’li hasta tedavi almayan kontrol grubunu (grup II) oluşturdu. BULGULAR: İlk başvuruda subklinik hipotiroidili hastalarda ötiroid olanlara göre, açlık ve postprandial glukoz, açlık sT4 ve sT3 düzeyleri anlamlı olarak daha düşükken, açlık TSH düzeyi daha yüksekti. Diğer parametrelerde anlamlı farklılık saptanmadı. Bu sonuçlara göre hastaların SH’li olup olmamasının hastaların açlık veya postprandiyal kolestrol düzeylerini etkilemediği görülmüştür. Üçüncü ay sonunda subklinik hipotiroidili tedavi alan (grup 1) ve tedavi almayan (Grup 2) gruplar arasında bazal ve postprandial değerler kıyaslandı. Tedavi almayan grupta açlık ve postprandial total kolesterol ve TSH değerleri istatiksel açıdan anlamlı olarak daha yüksekken, sT4 ve sT3 değerleri anlamlı olarak düşüktü. Ancak kolestrol seviyelerinde değişim miktarı (delta 0-3 ay) bakıldı ve istatistiksel fark izlenmedi. TARTIŞMA ve SONUÇ: Çalışmamızda SH’li hastalarda ötiroid kontrol grubu ile karşılaştırıldığında; hem açlık, hem de postprandial dönemde aterojenik kolesterol profili açısından farklılık saptanmamıştır. Tiroksin tedavisi ile açlık veya postprandial kolesterol düzeylerinde iyileşme tespit edilmemiştir.

Cholesterol Levels in Subclinical Hypothyroidism and the Effect of Levothyroxine Treatment on Cholesterol Levels

INTRODUCTION: In this study, fasting and postprandial cholesterol levels were investigated in patients diagnosed with subclinical hypothyroidism (SH), and it was investigated whether thyroxine treatment had an effect on these cholesterol levels. METHODS: Newly diagnosed 50 SH and 25 euthyroid patients were included in the study. The first 25 patients with SH were the treatment group (group I) and the second 25 patients with SH were the control group without treatment (group II). RESULTS: At the first admission, fasting and postprandial glucose, fasting fT4 and fT3 levels were significantly lower in patients with subclinical hypothyroidism compared to euthyroid patients, while fasting TSH levels were higher. There was no significant difference in other parameters. According to these results, it was observed that whether the patients had SH or not did not affect the fasting or postprandial cholesterol levels of the patients. At the end of the third month, basal and postprandial values were compared between the groups that received treatment with subclinical hypothyroidism (group 1) and those who did not receive treatment (Group 2). While fasting and postprandial total cholesterol and TSH values were statistically significantly higher in the untreated group, fT4 and fT3 values were significantly lower. However, the amount of change in cholesterol levels (delta 0-3 months) was evaluated and no statistical difference was observed. DISCUSSION AND CONCLUSION: No difference was found in terms of cholesterol profile in both fasting and postprandial periods in patients with SH compared to euthyroid control group. There was no improvement in fasting or postprandial cholesterol levels with thyroxine treatment.

PDF

___

1- Fatourechi V. Subclinical hypothyroidism: an update for primary care physicians. Mayo Clin Proc. 2009; 84(1): 65-71.
2- Delitala AP, Scuteri A, Maioli M, Mangatia P, Vilardi L, Erre GL. Subclinical hypothyroidism and cardiovascular risk factors. Minerva Med. 2019; 110(6): 530-45.
3- Földes J, Bános C, Winkler G. Szubklinikus hypothyreosis és arteriosclerosis [Subclinical hypothyroidism and arteriosclerosis]. Orv Hetil. 2004; 145(31): 1601-7.
4- Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000; 160(4): 526-34.
5- Hussain A, Elmahdawi AM, Elzeraidi NE, Nouh F, Algathafi K. The Effects of Dyslipidemia in Subclinical Hypothyroidism. Cureus. 2019; 11(11): 6173.
6- Nyström E, Caidahl K, Fager G, Wikkelsö C, Lundberg PA, Lindstedt G. A double-blind cross-over 12-month study of L-thyroxine treatment of women with 'subclinical' hypothyroidism. Clin Endocrinol (Oxf). 1988; 29(1): 63-75.
7- Kung AW, Pang RW, Janus ED. Elevated serum lipoprotein(a) in subclinical hypothyroidism. Clin Endocrinol (Oxf). 1995; 43(4): 445-9.
8- Ineck BA, Ng TM. Effects of subclinical hypothyroidism and its treatment on serum lipids. Ann Pharmacother. 2003; 37(5): 725-30.
9- Geul KW, van Sluisveld IL, Grobbee DE, Docter R, de Bruyn AM, Hooykaas H, et al. The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle-aged women: associations with serum lipids. Clin Endocrinol (Oxf). 1993; 39(3): 275-80.
10- Bigos ST, Ridgway EC, Kourides IA, Maloof F. Spectrum of pituitary alterations with mild and severe thyroid impairment. J Clin Endocrinol Metab. 1978; 46(2): 317-25.
11- Kutty KM, Bryant DG, Farid NR. Serum lipids in hypothyroidism--a re-evaluation. J Clin Endocrinol Metab. 1978; 46(1): 55-6.
12- Duntas LH, Brenta G. A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism. Front Endocrinol (Lausanne). 2018; 9: 511.
13- Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010; 304(12): 1365-74.
14- Higgins V, Adeli K. Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment. EJIFCC. 2017; 28(3): 168-84.
15- Hueston WJ, Pearson WS. Subclinical hypothyroidism and the risk of hypercholesterolemia. Ann Fam Med. 2004; 2(4): 351-5.
16- Lindeman RD, Romero LJ, Schade DS, Wayne S, Baumgartner RN, Garry PJ. Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey. Thyroid. 2003; 13(6): 595-600. 17- Tuzcu A, Bahceci M, Gokalp D, Tuzun Y, Gunes K. Subclinical hypothyroidism may be associated with elevated high-sensitive c-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr J. 2005; 52(1): 89-94.
18- Al Sayed A, Al Ali N, Bo Abbas Y, Alfadhli E. Subclinical hypothyroidism is associated with early insulin resistance in Kuwaiti women. Endocr J. 2006; 53(5): 653-7.
19- Karthick N, Dillara K, Poornima KN, Subhasini AS. Dyslipidaemic changes in women with subclinical hypothyroidism. J Clin Diagn Res. 2013; 7(10): 2122-5.
20- Asranna A, Taneja RS, Kulshreshta B. Dyslipidemia in subclinical hypothyroidism and the effect of thyroxine on lipid profile. Indian J Endocrinol Metab. 2012; 16(2): 347-9.
21- Tanis BC, Westendorp GJ, Smelt HM. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol (Oxf). 1996; 44(6): 643-9.
22- Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab. 2000; 85(9): 2993-3001.
23- Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab. 2001; 86(10): 4860-6.